Thomas Gad | Founder, Chairman & President |
Claus Moller | Chief Executive Officer |
Bo Kruse | Chief Financial Officer |
David Lebowitz | Morgan Stanley |
Alec Stranahan | Bank of America |
Etzer Darout | Guggenheim |
Joe Thome | Cowen |
Robert Burns | HC Wainwright |
Peter Lawson | Barclays |
Tessa Romero | JPMorgan |
Good day and welcome to the Y-mAbs Therapeutics Incorporated First Quarter 2021 Earnings Conference Call. Today's conference is being recorded.
Let me quickly remind you that the following discussion contains certain statements that are considered forward-looking statements as defined in the Private Security Liquidations Reform Act of 1995. Because forward-looking statements involve risks and uncertainties, they are not guarantees of future performance and actual results may differ materially from those expressed or implied by these forward-looking statements due to a variety of factors, including the fiscal year ended December 31, 2021 as filed with the SEC on March 1, 2021 and in the Company's subsequently filed SEC reports. At this time, I would like to turn the conference over to Thomas Gad, the Company's Founder, Chairman and President.